MO -- Q1 2026 Earnings Preview
Altria's Q1 print is a durability test, not a growth story. The company guided FY2026 adjusted diluted EPS to $5.56 to $5.72, or 2.5% to 5.5% growth, but the business exited Q4 with net revenues of $5.85B, adjusted EPS of $1.30, and Marlboro retail share down to 39.8%.
The stock is still supported by cash return and category pricing power, but the earnings question is whether price/mix and buybacks can keep covering cigarette volume decline while on!, NJOY, and the broader smoke-free portfolio remain too small to change the consolidated algorithm.
| Metric | FY2026 Guide / Setup | Read-through | |---|---:|---| | Adjusted diluted EPS low | $5.56 | Implies defensive, low-single-digit growth | | Adjusted diluted EPS high | $5.72 | Requires price/mix, tax, and buyback help | | Adjusted EPS growth low | 2.5% | Lower end likely if smokeable volumes worsen | | Adjusted EPS growth high | 5.5% | Needs stable Marlboro share and oral recovery | | Share repurchase capacity | $1.0B remaining under program per company press release | Supports EPS even if revenue stays pressured |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |---|---:|---:|---:|---:| | Net revenue | $5.26B | $6.10B | $6.07B | $5.85B | | Adjusted diluted EPS | $1.23 | $1.44 | $1.45 | $1.30 | | Total cigarette shipment volume | 14.20B sticks | 16.07B sticks | 16.19B sticks | 15.29B sticks | | Marlboro retail share | 41.0% | 41.0% | 40.4% | 39.8% | | on! shipment volume | 39.3M | 52.1M | 42.2M | 44.2M | | Oral tobacco net revenue | $654M | $753M | $689M | $706M |
The core smokeable franchise remains extraordinarily profitable, but the leading indicators are deteriorating. Total cigarette shipments were 15.29B sticks in Q4, down from 16.59B sticks in Q4 2024, while the adjusted domestic cigarette shipment change improved to -7.0% but remains structurally negative. Marlboro share below 40% matters because the investment case depends on premium pricing power staying intact.
Smoke-free is the offset, but the numbers are still mixed. on! shipment volume rebounded from Q3 to 44.2M cans, yet retail share slipped to 7.7%. NJOY data are stale in Daloopa beyond Q1 2025, when consumables shipments were 13.5M and device shipments were only 0.3M. The call needs concrete evidence that product availability, innovation, and FDA enforcement are moving the smoke-free portfolio back toward relevance.
| Catalyst | Timing | What Matters | |---|---|---| | Q1 cigarette volumes | Apr 30 | Whether the adjusted volume decline stays near Q4's -7.0% or worsens | | Marlboro share | Apr 30 | Stabilization after falling to 39.8% | | on! PLUS / oral nicotine | 2026 | Volume acceleration and retail share recovery | | NJOY reset | 2026 | Product availability, share, and path after weak latest shipment data | | Capital return | 2026 | Buybacks plus dividend support while fundamentals remain low growth |
| Date | Item | Read-through | |---|---|---| | Apr 16, 2026 | Altria scheduled Q1 results for Apr 30 before the open | Confirms this week's event | | Jan 29, 2026 | FY2026 EPS guide set at $5.56-$5.72 / high | Hurdle is guidance credibility, not acceleration | | Q4 2025 | Marlboro share fell to 39.8% | Watch for further premium share leakage | | Q4 2025 | Oral adjusted OCI margin fell to 64.5% | Smoke-free growth must not come at excessive margin cost |
| Quarter | Adjusted EPS | Operating Read | |---|---:|---| | Q4 2025 | $1.30 | Flat EPS, lower Marlboro share, smokeable pressure | | Q3 2025 | $1.45 | EPS supported by pricing and cost control | | Q2 2025 | $1.44 | Strongest 2025 EPS quarter, but volumes still negative | | Q1 2025 | $1.23 | Low base for the upcoming comparison |